Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults
- PMID: 16586358
- DOI: 10.1086/503050
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults
Abstract
Background: Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine.
Methods: In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA.
Results: Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA.
Conclusions: Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.
Similar articles
-
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27. Vaccine. 2009. PMID: 19716456 Clinical Trial.
-
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.J Infect Dis. 2006 Nov 15;194(10):1394-7. doi: 10.1086/508493. Epub 2006 Oct 6. J Infect Dis. 2006. PMID: 17054068 Clinical Trial.
-
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.Vaccine. 2007 May 10;25(19):3871-8. doi: 10.1016/j.vaccine.2007.01.106. Epub 2007 Feb 15. Vaccine. 2007. PMID: 17337102
-
Reduced-dose influenza vaccine.Ann Pharmacother. 2006 Sep;40(9):1635-9. doi: 10.1345/aph.1G645. Epub 2006 Jul 11. Ann Pharmacother. 2006. PMID: 16835314 Review.
-
Changing perspective on immunization against influenza.Vaccine. 2007 Apr 20;25(16):3062-5. doi: 10.1016/j.vaccine.2007.01.030. Epub 2007 Jan 19. Vaccine. 2007. PMID: 17276554 Review.
Cited by
-
WSSV ie1 promoter is more efficient than CMV promoter to express H5 hemagglutinin from influenza virus in baculovirus as a chicken vaccine.BMC Microbiol. 2008 Dec 31;8:238. doi: 10.1186/1471-2180-8-238. BMC Microbiol. 2008. PMID: 19116038 Free PMC article.
-
A changing trend in diagnostic methods of Influenza A (H3N2) virus in human: a review.3 Biotech. 2021 Feb;11(2):87. doi: 10.1007/s13205-021-02642-w. Epub 2021 Jan 20. 3 Biotech. 2021. PMID: 33495723 Free PMC article. Review.
-
Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.Drugs. 2013 Aug;73(12):1357-66. doi: 10.1007/s40265-013-0103-6. Drugs. 2013. PMID: 23928902 Review.
-
A launch vector for the production of vaccine antigens in plants.Influenza Other Respir Viruses. 2007 Jan;1(1):19-25. doi: 10.1111/j.1750-2659.2006.00005.x. Influenza Other Respir Viruses. 2007. PMID: 19453476 Free PMC article. Review.
-
Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice.Virol J. 2011 Nov 29;8:524. doi: 10.1186/1743-422X-8-524. Virol J. 2011. PMID: 22126628 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
